Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... researchers are still looking for more accessible and affordable treatments for all forms of AMD. Since AMD is closely ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Light therapy could be a useful treatment for the most common form of age-related macular degeneration, a new study says.

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Patients with neovascular age-related macular degeneration diagnosed by a primary care clinician may be more likely to miss ...

• Compared to human experts, artificial intelligence (AI)-based tests may be comparably accurate at detecting the exudative (or wet) form of age-related macular degeneration (eAMD). • There were no ...